InventisBio Co (688382.SS) Stock Price

InventisBio Co Price

CLOSED
14.45
​
Market closed

Revenue at InventisBio Co has contracted by 55.2% per year over the past 2 years to 37.29 M CNY. For InventisBio Co, the net margin of -849.7% is down versus -153.1% a few years ago. The consensus 12-month price target for InventisBio Co is 50.24 CNY, about 247.6% above where the stock trades today. Of 6 analysts, 5 rate the stock a buy — an overall Buy consensus.

InventisBio Co stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

InventisBio Co business model & stock analysis

InventisBio Co Ltd, headquartered in Shanghai, China, operates in the Health Care sector within the Biotechnology industry. The company employs 222 full-time staff and completed its IPO on July 25, 2022. InventisBio focuses on drug research and development for major diseases including tumors and metabolic conditions. Its core products under clinical development include D-0120, D-0502, D-1553, and BPI-D0316, targeting oncology and metabolic disease areas.

Frequently asked questions about InventisBio Co

Analysts currently set an average price target of 50.24 CNY for the InventisBio Co stock (median: 50.24 CNY), implying +262.7 % versus the latest price. The consensus is based on 6 analyst ratings.

6 analysts currently rate the InventisBio Co stock: 5 recommend buying, 1 holding and 0 selling. For 2026, analysts expect InventisBio Co to generate revenue of 149.00 M CNY and earnings per share of -0.52 CNY.

Converted at the current exchange rate, the InventisBio Co share trades at 1.94 EUR (14.45 CNY).

The expected revenue of InventisBio Co is 149.00 M CNY. This figure is based on current financial data and reflects the company's business performance.

The expected profit of InventisBio Co is -299.75 M CNY. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of InventisBio Co is currently -27.88. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the InventisBio Co stock.

The price-to-sales ratio (P/S) of InventisBio Co is currently 56.09. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the InventisBio Co stock.

The Eulerpool Quality Score for InventisBio Co is 3/10.

The ISIN of InventisBio Co is CNE100005Q22. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of InventisBio Co is 688382.SS. The ticker symbol is used to trade InventisBio Co shares on the stock exchange.

Fair ValueTerminal
12.28 CNY
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue per Employee
167,971.44 CNY
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
Currency
CNY
Initial public offering
Jul 25, 2022
ISIN
CNE100005Q22
Cusip
Y4108P100
Market capitalization
8.33 B CNYMid Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2026
-27.88
P/Ee 2027
-43.93
P/Ee 2028
—
P/Ee 2029
—
P/Se
56.09
EV/EBIT
—
P/B Ratio
5.42
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-20.63 %
Last updated Nov 7, 2026, 3:36 AM

InventisBio Co Peer Group

InventisBio Co FIGI

688382:CH · BBG00Y5Z68T7688382:CG · BBG0104BFG34688382:C1 · BBG01HWJLJK7

All fundamentals and in-depth analysis of InventisBio Co

Our stock analysis for InventisBio Co stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of InventisBio Co. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.